ALPS Medical Breakthroughs ETF
Market Price
NAV
NAV Change
Daily Return
Net Assets
YTD Return
Trailing Twelve Month Yield
ETFguide Spotlight: SBIO
Featuring Paul Baiocchi, Chief ETF Strategist, SS&C ALPS Advisors
Paul Baiocchi is a Registered Representative of ALPS Distributors, Inc. and ALPS Portfolio Solutions Distributor, Inc.
Overview
Investment Objective
The ALPS Medical Breakthroughs ETF (SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (PMBI).
Strategy
The ALPS Medical Breakthroughs ETF (SBIO) provides exposure to small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the US Food and Drug Administration clinical trials. Constituents must have a market capitalization of no less than $200 million and no more than $5 billion.
Fund Details
Ticker
|
Listing Exchange
NYSE Arca |
CUSIP
|
ISIN
|
Net Assets
as of
|
Inception Date |
Fund Type Exchange-Traded Fund |
Primary Benchmark S-Network Medical Breakthroughs Index |
Performance and Fees
Returns
As of
Total Returns | |
---|---|
As of
Total Returns | |
---|---|
As of
Performance data quoted represents past performance. Past performance is no guarantee of future results so that shares, when redeemed, may be worth more or less than their original cost. The investment return and principal value will fluctuate. Current performance may be higher or lower than the performance quoted. For current month-end performance call 1-866-759-5679 or visit www.alpsfunds.com. Performance includes reinvested distributions and capital gains.
Market Price is based on the midpoint of the bid/ask spread at 4 p.m. ET and does not represent the returns an investor would receive if shares were traded at other times.
Fund inception date: 12/30/2014
S-Network Medical Breakthroughs Index: comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the US Food and Drug Administration (“FDA”) clinical trials.
NASDAQ Biotechnology Index: designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index.
One may not invest directly in an index.
$10,000 Hypothetical Investment
The chart above represents the total return historical performance of a hypothetical investment of $10,000 in the Fund over the life of the Fund. Performance calculations are as of the end of each month. Past performance is no guarantee of future results. This chart does not reflect the deduction of taxes that a shareholder would pay on Fund distributions or the redemption of Fund shares.
Fees
Facts and Characteristics
Fund Pricing
As of
Market Price | |
NAV | |
NAV Change | |
Premium/Discount | |
Premium/Discount Difference | |
Daily Return | |
YTD Return | |
Last Trade Price (EOD) | |
Intraday (Midpoint) Price as of |
|
Total Market Value |
Trading Characteristics
As of
Shares Outstanding | |
Average 30-Day Volume | |
Daily Volume as of |
|
Dollar Volume | |
Net Create/Redeems | |
30-Day Median Bid/Ask Spread |
Fund Yields
Trailing Twelve Month Yield |
|
30-Day SEC Yield |
|
30-Day SEC Yield (Unsubsidized) |
Trailing Twelve Month Yield: refers to the percentage of income a portfolio has returned to investors over the last 12 months.
30-Day SEC Yield: reflects the dividends and interest earned during the period, after the deduction of the Fund's expenses.
30-Day SEC Yield (Unsubsidized): reflects the dividends and interest earned during the period, after the deduction of the Fund’s expenses, excluding fee waivers.
Risk Metrics
For the 3 years ending
Standard Deviation | ||
---|---|---|
Sharpe Ratio | ||
Sortino Ratio | ||
Fund vs Index1 | Fund vs Index2 | |
Alpha | ||
Beta | ||
R-Squared | ||
Tracking Error | ||
Upside Capture | ||
Downside Capture |
Portfolio
Sector Breakdown
- Top Five Holdings
Company Name | % of Fund |
---|
Geography Breakdown
- Top Five Holdings
Company Name | % of Fund |
---|
Fund Holdings
Funds Related to SBIO
ALPS Clean Energy ETF
ALPS Disruptive Technologies ETF
ALPS Global Travel Beneficiaries ETF
Fund Disclosure
Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemable.
The Fund’s investments are concentrated in the pharmaceuticals and biotechnology industries, and underperformance in these areas will result in underperformance in the Fund. Investments in small and micro capitalization companies are more volatile than companies with larger market capitalizations. Companies in the pharmaceuticals and biotechnology industry may be subject to extensive litigation based on product liability and similar claims. Legislation introduced or considered by certain governments on such industries or on the healthcare sector cannot be predicted.
Companies in the pharmaceuticals industry are subject to competitive forces that may make it difficult to raise prices and, in fact, may result in price discounting. The profitability of some companies in the pharmaceuticals industry may be dependent on a relatively limited number of products. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the pharmaceuticals industry are subject to government approvals, regulation and reimbursement rates. The process of obtaining government approvals may be long and costly. Many companies in the pharmaceuticals industry are heavily dependent on patents and intellectual property rights. The loss or impairment of these rights may adversely affect the profitability of these companies.
The development of new drugs generally has a high failure rate, and such failures may negatively impact the stock price of the company developing the failed drug. Biotechnology companies may have persistent losses during a new product’s transition from development to production. In order to fund operations, biotechnology companies may require financing from the capital markets, which may not always be available on satisfactory terms or at all.
The Fund is considered nondiversified and as a result may experience greater volatility than a diversified fund.
The Fund employs a “passive management” - or indexing - investment approach and seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index. Unlike many investment companies, the Fund is not “actively” managed. Therefore, it would not necessarily sell or buy a security unless that security is removed from or added to the underlying index, respectively.
ALPS Advisors, Inc., registered investment adviser with the SEC, is the investment adviser to the Fund. ALPS Advisors, Inc. is affiliated with ALPS Portfolio Solutions Distributor, Inc.
ALPS Portfolio Solutions Distributor, Inc. is the distributor for the Fund.